assignment
Not Recruiting

Phase 3 Randomized Study of Sitravatinib and Nivolumab Versus Docetaxel in Advanced Non-Squamous NSCLC Post-Platinum and Checkpoint Inhibitor Therapy

Trial ID
2024-516598-60-00
Protocol
516-005

Register record, history and transparency: CTIS.eu

Trial statistics

science
4
test molecules
location_city
8
research sites
public
3
countries
medical_information
1
disease
person_search
8
investigators
handshake
11
vendors

Diseases & Conditions

Non-small cell lung cancer

Objectives

The primary objective of this study is to compare **Overall Survival (OS)** in patients with advanced non-squamous non-small cell lung cancer (NSCLC) who have experienced disease progression on or after platinum-based chemotherapy and checkpoint inhibitor therapy (CIT). The comparison is between treatment with sitravatinib in combination with nivolumab versus docetaxel. This objective is clinically relevant as it aims to determine the efficacy of the combination therapy in extending the survival of patients with this specific type of lung cancer, which is crucial for improving patient outcomes.

Secondary objectives include:

  • Evaluating the safety of sitravatinib in combination with nivolumab in the study population.
  • Assessing the relative tolerability of sitravatinib and nivolumab versus docetaxel.
  • Evaluating secondary efficacy endpoints in the study population.
  • Investigating the pharmacokinetics (PK) of sitravatinib (MGCD516) administered in combination with nivolumab.
  • Assessing health-related quality of life and lung cancer-specific symptoms in the study population.

Participants

The clinical trial involves a total of **268 participants** diagnosed with **Advanced Non-Squamous Non-Small Cell Lung Cancer**. The study population includes both male and female subjects, with an age range that encompasses adults and older adults. Participants were selected based on their prior treatment history, specifically those who have experienced disease progression following platinum-based chemotherapy and checkpoint inhibitor therapy. The trial does not exclude vulnerable populations, indicating a broad inclusion of individuals who meet the specified criteria. Participants are required to have received at least one but not more than two prior treatment regimens in the advanced setting, with the most recent regimen including a checkpoint inhibitor therapy. The trial aims to compare overall survival in patients treated with sitravatinib and nivolumab versus docetaxel. Lifestyle factors such as diet and physical activity are not specified as part of the selection criteria.

Plans and Procedures

The clinical trial is designed as a **randomized**, **double-blind**, and controlled study to evaluate the efficacy and safety of **sitravatinib** in combination with **nivolumab** compared to **docetaxel** in patients with advanced non-squamous non-small cell lung cancer (NSCLC) who have experienced disease progression following platinum-based chemotherapy and checkpoint inhibitor therapy. The primary objective is to compare overall survival (OS) between the treatment groups. Secondary endpoints include safety assessments, objective response rate (ORR), duration of response (DOR), clinical benefit rate (CBR), progression-free survival (PFS), 1-year survival rate, blood plasma concentrations of MGCD516, and patient-reported outcomes using the Lung Cancer Symptom Scale (LCSS) and the European Quality of Life Five Dimensions Questionnaire (EQ-5D-5L).

The trial is expected to last until December 31, 2024, with recruitment having commenced on December 18, 2020. Participants will be involved in the study for the duration of their treatment period, which is determined by their response to the therapy and the occurrence of any adverse events. The study includes several key visits: an initial screening visit to confirm eligibility based on inclusion criteria such as a diagnosis of non-squamous NSCLC and prior treatment history, regular follow-up visits to monitor treatment response and safety, and an end-of-study visit to assess final outcomes and collect data on long-term effects.

Participants may be withdrawn from the study early if they experience unacceptable toxicity, disease progression, or if they choose to withdraw consent. The trial is conducted in compliance with ethical standards and regulatory requirements, ensuring the safety and well-being of all participants. The study's design and methodology are structured to provide robust data on the comparative effectiveness of the investigational treatment regimen versus the standard care option, contributing valuable insights into the management of advanced NSCLC.

Treatment

The clinical trial involves the administration of **Sitravatinib**, an experimental medication provided in the form of a hard capsule. The active substance in this medication is **sitravatinib malate**, a chemical compound. The maximum daily dose is 100 mg, with a total maximum dose of 16,800 mg over the treatment period. The medication is administered orally, and the treatment duration is not explicitly limited, allowing for continuous administration as required by the study protocol. Participant compliance with the dosing schedule is monitored throughout the trial to ensure adherence to the prescribed regimen.

**Nivolumab**, marketed as OPDIVO, is another experimental treatment used in this study. It is provided as a concentrate for solution for infusion, with the active substance being **nivolumab**, a protein of biological/biotechnological origin. The maximum daily dose is 480 mg, with a total maximum dose of 2,880 mg. This medication is administered intravenously, and similar to sitravatinib, the treatment period is not explicitly limited. Compliance with the administration schedule is closely monitored to ensure accurate dosing.

The comparator treatment in this trial is **Docetaxel**, marketed as TAXOTERE, which is provided as a concentrate for solution for infusion. The active substance is **docetaxel**, a chemical compound. The maximum daily dose is 75 mg/m², with a total maximum dose of 450 mg/m². This medication is administered intravenously. As with the other treatments, the administration schedule is monitored to ensure participant compliance and accurate dosing throughout the trial.

Efficacy

The efficacy of the clinical trial will be assessed primarily through the measurement of **Overall Survival (OS)** in patients with advanced non-squamous non-small cell lung cancer (NSCLC) who have experienced disease progression following platinum-based chemotherapy and checkpoint inhibitor therapy. The trial involves a comparison between the combination of sitravatinib and nivolumab versus docetaxel. Secondary efficacy endpoints include the **Objective Response Rate (ORR)** as defined by the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), **Duration of Response (DOR)**, **Clinical Benefit Rate (CBR)**, **Progression-Free Survival (PFS)**, and the **1-Year Survival Rate**.

Additional assessments will include blood plasma concentrations of MGCD516 and patient-reported outcomes (PROs) using the Lung Cancer Symptom Scale (LCSS) and the European Quality of Life Five Dimensions Questionnaire (EQ-5D-5L). The safety profile will also be characterized by evaluating the type, incidence, severity, timing, seriousness, and relationship to study treatment of adverse events, laboratory abnormalities, and the number of patients discontinuing study treatment due to adverse events. These parameters will be collected and analyzed at specified intervals throughout the trial to ensure comprehensive evaluation of the treatment's efficacy and safety.

Inclusion and Exclusion Criteria

check_circle

Inclusion Criteria

  • Diagnosis of Non-Squamous Non-Small Cell Lung Cancer
  • Receipt of at least one but not more than two prior treatment regimens in the advanced setting
  • Prior treatment with PD-1/PD-L1 checkpoint inhibitor therapy and platinum-based chemotherapy in combination or in sequence (i.e., platinum-based chemotheraphy followed by checkpoint inhibitor therapy)
  • Most recent treatment regimen must have included a checkpoint inhibitor therapy with radiographic disease progression on or after treatment
  • Candidate to receive docetaxel as second or third line therapy
cancel

Exclusion Criteria

  • Uncontrolled brain metastases
  • Tumors that have tested positive for EGFR, ROS1, ALK mutations, or ALK fusions
  • Unacceptable toxicity with prior checkpoint inhibitor therapy
  • Receipt of systemic anti-cancer therapy post checkpoint inhibitor therapy, other than maintenance chemotherapy
  • Impaired heart function

Trial Status by Country

Country Status Start of Recruitment Planned Patients
Italy ItalyNot Recruiting18 Dec 202047
The Netherlands The NetherlandsNot Recruiting18 Dec 2020—
Spain SpainNot Recruiting18 Dec 202081
Netherlands Netherlands——68

Sites & Investigators

Investigational Products

Details about the medicinal products being studied in this clinical trial.

Product Name Role in Trial Formulation Administration Max Daily Dose Treatment Duration EU MP Number
Sitravatinib
TestCAPSULE, HARDORAL USE100.009999999PRD11290100
Sitravatinib
TestCAPSULE, HARDORAL USE100.009999999PRD11290108
TAXOTERE 20 mg/1 ml concentrate for solution for infusion
ComparatorCONCENTRATE FOR SOLUTION FOR INFUSIONINTRAVENOUS USE75.009999999PRD479192
OPDIVO 10 mg/mL concentrate for solution for infusion.
TestCONCENTRATE FOR SOLUTION FOR INFUSIONINTRAVENOUS USE480.009999999PRD2941375

Conditions Studied in This Trial

Interventions Studied in This Trial

vaccines
Docetaxel
139 trials

Also investigated for

Non-small cell lung cancer 27Hormone-refractory prostate cancer 18Oesophageal adenocarcinoma 11Non-small cell lung cancer metastatic 8
vaccines
Nivolumab
217 trials

Also investigated for

Non-small cell lung cancer 26Malignant melanoma 23Neoplasm 17Renal cell carcinoma 14
vaccines
Sitravatinib Malate
2 trials

Also investigated for

Non-small cell lung cancer 1Uveal melanoma 1